

# Paul J Declerck

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7783939/publications.pdf>

Version: 2024-02-01

253  
papers

7,373  
citations

57758

44  
h-index

91884

69  
g-index

260  
all docs

260  
docs citations

260  
times ranked

6638  
citing authors

#	ARTICLE	IF	CITATIONS
1	The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. <i>FASEB Journal</i> , 2002, 16, 147-154.	0.5	260
2	Effectiveness of the Electronic Cigarette: An Eight-Week Flemish Study with Six-Month Follow-up on Smoking Reduction, Craving and Experienced Benefits and Complaints. <i>International Journal of Environmental Research and Public Health</i> , 2014, 11, 11220-11248.	2.6	177
3	Age-Dependent Spontaneous Coronary Arterial Thrombosis in Transgenic Mice That Express a Stable Form of Human Plasminogen Activator Inhibitor-1. <i>Circulation</i> , 2002, 106, 491-496.	1.6	173
4	Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 49-57.	3.8	169
5	Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth. <i>Oncogene</i> , 2004, 23, 6986-6990.	5.9	151
6	Comparison of random and oriented immobilisation of antibody fragments on mixed self-assembled monolayers. <i>Journal of Immunological Methods</i> , 2006, 312, 167-181.	1.4	144
7	Three Decades of Research on Plasminogen Activator Inhibitor-1: A Multifaceted Serpin. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 356-364.	2.7	141
8	Plasminogen activator inhibitor-1 modulates adipocyte differentiation. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2006, 290, E103-E113.	3.5	113
9	Realization and Characterization of Porous Gold for Increased Protein Coverage on Acoustic Sensors. <i>Analytical Chemistry</i> , 2004, 76, 4299-4306.	6.5	111
10	The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects. <i>Drugs</i> , 2017, 77, 671-677.	10.9	106
11	Mechanisms contributing to the conformational and functional flexibility of plasminogen activator inhibitor-1. <i>Nature Structural Biology</i> , 1995, 2, 891-897.	9.7	104
12	Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics. , 2019, 7, 105.		103
13	The Biochemistry, Physiology and Pathological roles of PAI-1 and the requirements for PAI-1 inhibition in vivo. <i>Thrombosis Research</i> , 2012, 130, 576-585.	1.7	100
14	Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation. <i>Journal of Molecular Biology</i> , 2000, 297, 683-695.	4.2	94
15	The structural basis for the pathophysiological relevance of PAI-1 in cardiovascular diseases and the development of potential PAI-1 inhibitors. <i>Thrombosis and Haemostasis</i> , 2004, 91, 425-437.	3.4	91
16	Immunoassay of Murine t-PA, u-PA and PAI-1 Using Monoclonal Antibodies Raised in Gene-inactivated Mice. <i>Thrombosis and Haemostasis</i> , 1995, 74, 1305-1309.	3.4	90
17	PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin. <i>Nature Medicine</i> , 2014, 20, 741-747.	30.7	86
18	The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 734-755.	4.7	86

#	ARTICLE	IF	CITATIONS
19	Substrate Behavior of Plasminogen Activator Inhibitor-1 Is Not Associated with a Lack of Insertion of the Reactive Site Loop. <i>Biochemistry</i> , 1996, 35, 7474-7481.	2.5	81
20	The Market of Biopharmaceutical Medicines: A Snapshot of a Diverse Industrial Landscape. <i>Frontiers in Pharmacology</i> , 2017, 8, 314.	3.5	80
21	Development of a Genotype-Specific proCPU/TAFI ELISA. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 1122-1127.	2.4	79
22	Purification and characterization of natural and recombinant human plasminogen activator inhibitor-1 (PAI-1). <i>FEBS Journal</i> , 1988, 175, 531-540.	0.2	75
23	Plasminogen Activator Inhibitor-1. <i>Current Medicinal Chemistry</i> , 2004, 11, 2323-2334.	2.4	75
24	Hormonal Control of Plasminogen Activator Inhibitor-1 Gene Expression and Production in Human Adipose Tissue: Stimulation by Glucocorticoids and Inhibition by Catecholamines. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 4097-4105.	3.6	74
25	A Narrative Review on Plasminogen Activator Inhibitor-1 and Its (Patho)Physiological Role: To Target or Not to Target?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2721.	4.1	73
26	Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms. <i>BBA - Proteins and Proteomics</i> , 1997, 1337, 257-266.	2.1	70
27	Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 622473.	2.4	69
28	Accelerated Conversion of Human Plasminogen Activator Inhibitor-1 to Its Latent Form by Antibody Binding. <i>Journal of Biological Chemistry</i> , 1999, 274, 17511-17517.	3.4	67
29	Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies. <i>Frontiers in Pharmacology</i> , 2016, 7, 193.	3.5	65
30	The role of thrombin activatable fibrinolysis inhibitor in arterial thrombosis at a young age: the ATTAC study. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 919-927.	3.8	63
31	Thrombin Activatable Fibrinolysis Inhibitor Activation Peptide Shows Association With All Major Subtypes of Ischemic Stroke and With TAFI Gene Variation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 955-962.	2.4	62
32	Prevention of Renal Fibrin Deposition in Endotoxin-induced DIC through Inhibition of PAI-1. <i>Thrombosis and Haemostasis</i> , 2000, 84, 65-70.	3.4	59
33	Modulation of Plasminogen Activator Inhibitor 1 by Triton X-100 Identification of Two Consecutive Conformational Transitions. <i>Thrombosis and Haemostasis</i> , 1998, 80, 286-291.	3.4	58
34	Hyperthermia inhibits angiogenesis by a plasminogen activator inhibitor 1-dependent mechanism. <i>Cancer Research</i> , 2003, 63, 1500-7.	0.9	58
35	Comparative thrombolytic and immunogenic properties of staphylokinase and streptokinase. <i>Fibrinolysis</i> , 1992, 6, 232-242.	0.5	57
36	Conformational Studies on Plasminogen Activator Inhibitor (PAI-1) in Active, Latent, Substrate, and Cleaved Forms. <i>Biochemistry</i> , 1995, 34, 1064-1069.	2.5	56

#	ARTICLE	IF	CITATIONS
37	Recombinant Staphylokinase Variants With Altered Immunoreactivity. <i>Circulation</i> , 1996, 94, 197-206.	1.6	56
38	Inactivation of Plasminogen Activator Inhibitor-1 by Specific Proteolysis with Stromelysin-1 (MMP-3). <i>Journal of Biological Chemistry</i> , 2000, 275, 37645-37650.	3.4	52
39	Innovative thrombolytic strategy using a heterodimer diabody against TAFI and PAI-1 in mouse models of thrombosis and stroke. <i>Blood</i> , 2015, 125, 1325-1332.	1.4	52
40	Importance of the Hinge Region between $\hat{\pm}$ -Helix F and the Main Part of Serpins, Based upon Identification of the Epitope of Plasminogen Activator Inhibitor Type 1 Neutralizing Antibodies. <i>Journal of Biological Chemistry</i> , 2000, 275, 6375-6380.	3.4	50
41	Correlations between t-PA and PAI-1 antigen and activity and t-PA/PAI-1 complexes in plasma of control subjects and of patients with increased t-PA or PAI-1 levels. <i>Thrombosis Research</i> , 1990, 60, 509-516.	1.7	49
42	Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?. <i>Rheumatology and Therapy</i> , 2020, 7, 35-64.	2.3	49
43	Identification of a bacterial inhibitor against g-type lysozyme. <i>Cellular and Molecular Life Sciences</i> , 2011, 68, 1053-1064.	5.4	48
44	Biosimilar monoclonal antibodies: a science-based regulatory challenge. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 153-156.	3.1	48
45	Inhibition of Thrombin-Activatable Fibrinolysis Inhibitor and Plasminogen Activator Inhibitor-1 Reduces Ischemic Brain Damage in Mice. <i>Stroke</i> , 2016, 47, 2419-2422.	2.0	48
46	The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars. <i>British Journal of Cancer</i> , 2019, 121, 199-210.	6.4	48
47	Generation of Monoclonal Antibodies against Autologous Proteins in Gene-inactivated Mice. <i>Journal of Biological Chemistry</i> , 1995, 270, 8397-8400.	3.4	46
48	Biochemical importance of glycosylation of plasminogen activator inhibitor-1. <i>Thrombosis and Haemostasis</i> , 2003, 90, 206-217.	3.4	46
49	Dose-Dependent Modulation of Choroidal Neovascularization by Plasminogen Activator Inhibitor Type I: Implications for Clinical Trials. , 2003, 44, 2791.		45
50	State of play and clinical prospects of antibody gene transfer. <i>Journal of Translational Medicine</i> , 2017, 15, 131.	4.4	45
51	Harmonization of Infliximab and Anti-Infliximab Assays Facilitates the Comparison Between Originators and Biosimilars in Clinical Samples. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 969-975.	1.9	44
52	Modulation of TAFI function through different pathways - implications for the development of TAFI inhibitors. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 2745-2753.	3.8	43
53	Factor VIIâ€™Activating Protease Promotes the Proteolysis and Inhibition of Tissue Factor Pathway Inhibitor. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 427-433.	2.4	43
54	Generation and characterization of inhibitory nanobodies towards thrombin activatable fibrinolysis inhibitor. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 1302-1312.	3.8	40

#	ARTICLE	IF	CITATIONS
55	Urokinase-Type Plasminogen Activator Promotes Paracellular Transmigration of Neutrophils Via Mac-1, But Independently of Urokinase-Type Plasminogen Activator Receptor. <i>Circulation</i> , 2011, 124, 1848-1859.	1.6	40
56	Activation of both coagulation and fibrinolysis in childhood hemolytic uremic syndrome. <i>Kidney International</i> , 1998, 54, 1324-1330.	5.2	39
57	Lysozyme inhibitor conferring bacterial tolerance to invertebrate type lysozyme. <i>Cellular and Molecular Life Sciences</i> , 2010, 67, 1177-1188.	5.4	39
58	Development of a Universal Anti-Adalimumab Antibody Standard for Interlaboratory Harmonization. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 669-673.	2.0	39
59	Biosimilarity Versus Manufacturing Change: Two Distinct Concepts. <i>Pharmaceutical Research</i> , 2016, 33, 261-268.	3.5	39
60	In vitro reductive activation of nitroimidazoles. <i>Biochemical Pharmacology</i> , 1986, 35, 59-61.	4.4	38
61	Extending the capabilities of targeted molecular dynamics: Simulation of a large conformational transition in plasminogen activator inhibitor 1. <i>Protein Science</i> , 2001, 10, 798-808.	7.6	38
62	Evidence for a Pre-latent Form of the Serpin Plasminogen Activator Inhibitor-1 with a Detached $\beta$ -Strand 1C. <i>Journal of Biological Chemistry</i> , 2006, 281, 36071-36081.	3.4	38
63	Proteinase Specificity and Functional Diversity in Point Mutants of Plasminogen Activator Inhibitor 1. <i>Journal of Biological Chemistry</i> , 1997, 272, 12662-12666.	3.4	37
64	Development of ELISAs Measuring the Extent of TAFI Activation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 423-428.	2.4	37
65	Generation of a Highly Specific Monoclonal Anti-Infliximab Antibody for Harmonization of TNF-Coated Infliximab Assays. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 479-485.	2.0	37
66	An echistatin-like Arg-Gly-Asp (RGD)-containing sequence in the heavy chain CDR3 of a murine monoclonal antibody that inhibits human platelet glycoprotein IIb/IIIa function. <i>British Journal of Haematology</i> , 1994, 87, 562-571.	2.5	36
67	Evaluation of the profibrinolytic properties of an anti-TAFI monoclonal antibody in a mouse thromboembolism model. <i>Blood</i> , 2011, 117, 4615-4622.	1.4	36
68	The Distal Hinge of the Reactive Site Loop and Its Proximity. <i>Journal of Biological Chemistry</i> , 2001, 276, 44912-44918.	3.4	35
69	A European perspective on the market accessibility of biosimilars. <i>Biosimilars (Auckland, New Zealand)</i> , 0, , 33.	0.4	34
70	Mechanisms of Conversion of Plasminogen Activator Inhibitor 1 from a Suicide Inhibitor to a Substrate by Monoclonal Antibodies. <i>Journal of Biological Chemistry</i> , 2002, 277, 43858-43865.	3.4	32
71	A Camelid-derived Antibody Fragment Targeting the Active Site of a Serine Protease Balances between Inhibitor and Substrate Behavior. <i>Journal of Biological Chemistry</i> , 2016, 291, 15156-15168.	3.4	32
72	Thrombin Activatable Fibrinolysis Inhibitor (TAFI): An Updated Narrative Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3670.	4.1	32

#	ARTICLE	IF	CITATIONS
73	Reciprocal regulation of tissue-type and urokinase-type plasminogen activators in the differentiation of murine preadipocyte line 3T3-L1 and the hormonal regulation of fibrinolytic factors in the mature adipocytes. <i>Journal of Cellular Physiology</i> , 2001, 189, 72-78.	4.1	31
74	Defective TAFI activation in hemophilia A mice is a major contributor to joint bleeding. <i>Blood</i> , 2018, 132, 1593-1603.	1.4	31
75	Recombinant plasminogen activator inhibitor-1 reverses the bleeding tendency associated with the combined administration of tissue-type plasminogen activator and aspirin in rabbits. <i>Journal of Clinical Investigation</i> , 1989, 84, 586-591.	8.2	31
76	Characterization and Comparative Evaluation of a Novel PAI-1 Inhibitor. <i>Thrombosis and Haemostasis</i> , 2002, 88, 137-143.	3.4	30
77	His374 of wheat endoxylanase inhibitor TAXI-I stabilizes complex formation with glycoside hydrolase family 11 endoxylanases. <i>FEBS Journal</i> , 2005, 272, 5872-5882.	4.7	30
78	Biosimilars: controversies as illustrated by rhGH. <i>Current Medical Research and Opinion</i> , 2010, 26, 1219-1229.	1.9	30
79	Thrombin activatable fibrinolysis inhibitor. <i>Hamostaseologie</i> , 2011, 31, 165-173.	1.9	29
80	Identification of a Functional Epitope in Plasminogen Activator Inhibitor-1, not Localized in the Reactive Center Loop. <i>Thrombosis and Haemostasis</i> , 1998, 79, 597-601.	3.4	28
81	The story of the serpin plasminogen activator inhibitor 1: is there any need for another mutant?. <i>Thrombosis and Haemostasis</i> , 2004, 92, 898-924.	3.4	28
82	Targeting of Plasminogen Activator Inhibitor 1 Improves Fibrinolytic Therapy for Tetracycline-Induced Pleural Injury in Rabbits. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2015, 52, 429-437.	2.9	28
83	Reactive site-dependent phenotypic alterations in plasminogen activator inhibitor-1 transgenic mice. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 1500-1508.	3.8	27
84	Discovery of a novel conformational equilibrium in urokinase-type plasminogen activator. <i>Scientific Reports</i> , 2017, 7, 3385.	3.3	27
85	Dynamic structural and functional relationships in recombinant plasminogen activator inhibitor-1 (rPAI-1). <i>BBA - Proteins and Proteomics</i> , 1993, 1202, 221-229.	2.1	26
86	A Model of the Reactive Form of Plasminogen Activator Inhibitor-1. <i>Journal of Structural Biology</i> , 1994, 113, 239-245.	2.8	26
87	Generation of a Stable Activated Thrombin Activable Fibrinolysis Inhibitor Variant. <i>Journal of Biological Chemistry</i> , 2006, 281, 15878-15883.	3.4	26
88	Characterization of common neoantigenic epitopes generated in plasminogen activator inhibitor-1 after cleavage of the reactive center loop or after complex formation with various serine proteinases. <i>FEBS Letters</i> , 1995, 376, 243-246.	2.8	25
89	Biotherapeutics in the Era of Biosimilars. <i>Drug Safety</i> , 2007, 30, 1087-1092.	3.2	25
90	Elucidation of the epitope of a latency-inducing antibody: identification of a new molecular target for PAI-1 inhibition. <i>Thrombosis and Haemostasis</i> , 2003, 90, 52-58.	3.4	24

#	ARTICLE	IF	CITATIONS
91	The Roles of Selected Arginine and Lysine Residues of TAFI (Pro-CPU) in Its Activation to TAFIa by the Thrombin-Thrombomodulin Complex. <i>Journal of Biological Chemistry</i> , 2009, 284, 7059-7067.	3.4	24
92	Novel or expanding current targets in fibrinolysis. <i>Drug Discovery Today</i> , 2014, 19, 1476-1482.	6.4	24
93	Polarographic evidence for the interaction of reduced nitroimidazole derivatives with DNA bases. <i>Journal of the Chemical Society Faraday Transactions I</i> , 1987, 83, 257.	1.0	23
94	Crystallization and X-ray diffraction data of the cleaved form of plasminogen activator inhibitor-1. <i>Proteins: Structure, Function and Bioinformatics</i> , 1995, 23, 118-121.	2.6	23
95	Identification of a Target Site in Plasminogen Activator Inhibitor-1 That Allows Neutralization of Its Inhibitory Properties Concomitant with an Allosteric Up-regulation of Its Antiadhesive Properties. <i>Journal of Biological Chemistry</i> , 2001, 276, 26243-26248.	3.4	23
96	Announcing a TAFIa mutant with a 180-fold increased half-life and concomitantly a strongly increased antifibrinolytic potential. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 418-420.	3.8	23
97	A Peptide Accelerating the Conversion of Plasminogen Activator Inhibitor-1 to an Inactive Latent State. <i>Molecular Pharmacology</i> , 2008, 74, 641-653.	2.3	23
98	Plant pectin methylesterase and its inhibitor from kiwi fruit: Interaction analysis by surface plasmon resonance. <i>Food Chemistry</i> , 2010, 121, 207-214.	8.2	23
99	Thrombin Activatable Fibrinolysis Inhibitor: A Putative Target to Enhance Fibrinolysis. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 365-372.	2.7	23
100	Active PAI-1 as marker for venous thromboembolism: Caseâ€“control study using a comprehensive panel of PAI-1 and TAFI assays. <i>Thrombosis Research</i> , 2014, 134, 1097-1102.	1.7	23
101	Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1â€“Biosimilar and Originator Infliximab in the Hospital Setting. <i>BioDrugs</i> , 2019, 33, 285-297.	4.6	23
102	Expanding a Portfolio of (FO-) SPR Surface Chemistries with the Co(III)-NTA Oriented Immobilization of His<sub>6</sub>-Tagged Bioreceptors for Applications in Complex Matrices. <i>ACS Sensors</i> , 2020, 5, 960-969.	7.8	23
103	Base specific interaction of reductively activated nitroimidazoles with DNA. <i>FEBS Letters</i> , 1983, 164, 145-148.	2.8	22
104	Characterization of rat thrombin-activatable fibrinolysis inhibitor (TAFI) - a comparative study assessing the biological equivalence of rat, murine and human TAFI. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 2470-2477.	3.8	22
105	Biochemical Importance of Glycosylation in Thrombin Activatable Fibrinolysis Inhibitor. <i>Circulation Research</i> , 2008, 102, 295-301.	4.5	22
106	The hyperfibrinolytic state of mice with combined thrombinâ€“activatable fibrinolysis inhibitor (TAFI) and plasminogen activator inhibitorâ€“1 gene deficiency is critically dependent on TAFI deficiency. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 2555-2562.	3.8	22
107	Nebulized Fibrinolytic Agents Improve Pulmonary Fibrinolysis but Not Inflammation in Rat Models of Direct and Indirect Acute Lung Injury. <i>PLoS ONE</i> , 2013, 8, e55262.	2.5	22
108	Prolonged <i>in vivo</i> expression and anti-tumor response of DNA-based anti-HER2 antibodies. <i>Oncotarget</i> , 2018, 9, 13623-13636.	1.8	22

#	ARTICLE	IF	CITATIONS
109	Measurement of different forms of plasminogen activator inhibitor 1 (PAI-1) using various monoclonal antibody-based enzyme-linked immunosorbent assays. <i>Fibrinolysis</i> , 1990, 4, 132-133.	0.5	21
110	Effect of Stabilizing versus Destabilizing Interactions on Plasminogen Activator Inhibitor-1. <i>Thrombosis and Haemostasis</i> , 2000, 84, 871-875.	3.4	21
111	Additivity in Effects of Vitronectin and Monoclonal Antibodies against Î±-Helix F of Plasminogen Activator Inhibitor-1 on Its Reactions with Target Proteinases. <i>Journal of Biological Chemistry</i> , 2005, 280, 1482-1489.	3.4	21
112	Discovery of novel mechanisms and molecular targets for the inhibition of activated thrombin activatable fibrinolysis inhibitor. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1892-1899.	3.8	21
113	Subtle structural differences between human and mouse PAI-1 reveal the basis for biochemical differences. <i>Journal of Structural Biology</i> , 2010, 171, 95-101.	2.8	21
114	TAFIa inhibiting nanobodies as profibrinolytic tools and discovery of a new TAFIa conformation. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 2268-2277.	3.8	21
115	The road from development to approval: evaluating the body of evidence to confirm biosimilarity. <i>Rheumatology</i> , 2017, 56, iv4-iv13.	1.9	21
116	Monoclonal Antibody Biosimilars in Oncology: Critical Appraisal of Available Data on Switching. <i>Clinical Therapeutics</i> , 2018, 40, 798-809.e2.	2.5	21
117	An Enzyme-Linked Immunosorbent Assay for Urokinase-Type Plasminogen Activator (u-PA) and Mutants and Chimeras Containing the Serine Protease Domain of u-PA. <i>Thrombosis and Haemostasis</i> , 1992, 67, 095-100.	3.4	21
118	The importance of helix F in plasminogen activator inhibitor-1. <i>BBA - Proteins and Proteomics</i> , 2000, 1476, 20-26.	2.1	20
119	Identification and characterisation of monoclonal antibodies that impair the activation of human thrombin activatable fibrinolysis inhibitor through different mechanisms. <i>Thrombosis and Haemostasis</i> , 2011, 106, 90-101.	3.4	20
120	4 Pathophysiology of fibrinolysis. <i>Best Practice and Research: Clinical Haematology</i> , 1995, 8, 329-343.	1.1	19
121	Maximal PAI-1 inhibition in vivo requires neutralizing antibodies that recognize and inhibit glycosylated PAI-1. <i>Thrombosis Research</i> , 2012, 129, e126-e133.	1.7	19
122	Molecular forms of plasminogen activator inhibitor-1 (PAI-1) and tissue-type plasminogen activator (t-PA) in human plasma. <i>Thrombosis Research</i> , 1991, 62, 275-285.	1.7	18
123	Identification of positively charged residues contributing to the stability of plasminogen activator inhibitor 1. <i>FEBS Letters</i> , 1997, 415, 192-195.	2.8	18
124	Bispecific targeting of thrombin activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 by a heterodimer diabody. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1884-1891.	3.8	18
125	Remarkable Stabilization of Plasminogen Activator Inhibitor 1 in a "Molecular Sandwich" Complex. <i>Biochemistry</i> , 2013, 52, 4697-4709.	2.5	18
126	Haemostatic biomarkers are associated with long-term recurrent vascular events after ischaemic stroke. <i>Thrombosis and Haemostasis</i> , 2016, 116, 537-543.	3.4	18



#	ARTICLE	IF	CITATIONS
127	Evaluation of the mechanism of inactivation of plasminogen activator inhibitor-1 by monoclonal antibodies using a stable variant. <i>Fibrinolysis and Proteolysis</i> , 1998, 12, 277-282.	1.1	17
128	Elucidation of a novel epitope of a substrate-inducing monoclonal antibody against the serpin PAI-1. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 1028-1033.	3.8	17
129	Monoclonal antibodies targeting the antifibrinolytic activity of activated thrombin-activatable fibrinolysis inhibitor but not the anti-inflammatory activity on osteopontin and C5a. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 2137-2147.	3.8	17
130	Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin-activatable fibrinolysis inhibitor activation and activated thrombin-activatable fibrinolysis inhibitor activity. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 1629-1638.	3.8	17
131	Demystifying biosimilars: development, regulation and clinical use. <i>Future Oncology</i> , 2019, 15, 777-790.	2.4	17
132	Platelet activation and high tissue factor level predict acute stent thrombosis in pig coronary arteries: Prothrombogenic response of drug-eluting or bare stent implantation within the first 24 hours. <i>Thrombosis and Haemostasis</i> , 2006, 96, 202-209.	3.4	17
133	Importance of N-Terminal Residues in Plasminogen Activator Inhibitor 1 on its Antibody Induced Latency Transition. <i>Thrombosis and Haemostasis</i> , 2002, 88, 288-293.	3.4	16
134	Modulation of Serpin Reaction through Stabilization of Transient Intermediate by Ligands Bound to Î±-Helix F. <i>Journal of Biological Chemistry</i> , 2007, 282, 26306-26315.	3.4	16
135	High quality structure of cleaved PAI-1-stab. <i>Journal of Structural Biology</i> , 2009, 165, 126-132.	2.8	16
136	High thrombin activatable fibrinolysis inhibitor levels are associated with an increased risk of premature peripheral arterial disease. <i>Thrombosis Research</i> , 2011, 127, 254-258.	1.7	16
137	Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 2 – Biosimilar and Originator Etanercept in the Outpatient Setting. <i>BioDrugs</i> , 2019, 33, 299-306.	4.6	16
138	Development of anti-matrix metalloproteinase-2 (MMP-2) nanobodies as potential therapeutic and diagnostic tools. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2020, 24, 102103.	3.3	16
139	Regulatory Information and Guidance on Biosimilars and Their Use Across Europe: A Call for Strengthened One Voice Messaging. <i>Frontiers in Medicine</i> , 2022, 9, 820755.	2.6	16
140	Rational Design of Complex Formation between Plasminogen Activator Inhibitor-1 and Its Target Proteinases. <i>Journal of Structural Biology</i> , 1997, 118, 236-242.	2.8	15
141	Tryptophan Properties in Fluorescence and Functional Stability of Plasminogen Activator Inhibitor 1. <i>Biophysical Journal</i> , 2003, 85, 501-510.	0.5	15
142	Enhancement of endogenous fibrinolysis does not reduce local fibrin deposition, but modulates inflammation upon intestinal ischemia and reperfusion. <i>Thrombosis and Haemostasis</i> , 2004, 91, 497-505.	3.4	15
143	Migration of the activation peptide of thrombin-activatable fibrinolysis inhibitor (TAFI) during SDS-polyacrylamide gel electrophoresis. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 780-784.	3.8	15
144	Characterization of a panel of monoclonal antibodies toward mouse PAI-1 that exert a significant profibrinolytic effect in vivo. <i>Thrombosis Research</i> , 2011, 128, 68-76.	1.7	15

#	ARTICLE	IF	CITATIONS
145	Bridging the Clinical Gap for DNA-Based Antibody Therapy Through Translational Studies in Sheep. <i>Human Gene Therapy</i> , 2019, 30, 1431-1443.	2.7	15
146	DNA-Based Delivery of Checkpoint Inhibitors in Muscle and Tumor Enables Long-Term Responses with Distinct Exposure. <i>Molecular Therapy</i> , 2020, 28, 1068-1077.	8.2	15
147	Thrombin activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 268-276.	3.8	15
148	Immobilization of the Distal Hinge in the Labile Serpin Plasminogen Activator Inhibitor 1. <i>Journal of Biological Chemistry</i> , 2003, 278, 23899-23905.	3.4	14
149	Function-Stabilizing Mechanism of Plasminogen Activator Inhibitor Type 1 Induced upon Binding to Î±1-Acid Glycoprotein. <i>Biochemistry</i> , 2005, 44, 12384-12390.	2.5	14
150	Comparative evaluation of stable TAFI variants: importance of Î±1-helix 9 and Î±2-sheet 11 for TAFI (in)stability. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 2105-2112.	3.8	14
151	Development and evaluation of monoclonal antibodies as probes to assess the differences between two tomato pectin methylesterase isoenzymes. <i>Journal of Immunological Methods</i> , 2009, 349, 18-27.	1.4	14
152	Targeting the autolysis loop of urokinase-type plasminogen activator with conformation-specific monoclonal antibodies. <i>Biochemical Journal</i> , 2011, 438, 39-51.	3.7	14
153	Convalescent plasma levels of TAFI activation peptide predict death and recurrent vascular events in ischemic stroke survivors. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 725-727.	3.8	14
154	Plasmin and the thrombin-thrombomodulin complex both contribute to thrombin-activatable fibrinolysis inhibitor activation in whole blood model thrombi. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 190-192.	3.8	14
155	Identification of a novel, nanobody-induced, mechanism of TAFI inactivation and its in vivo application. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 229-236.	3.8	14
156	Generation and in vitro characterisation of inhibitory nanobodies towards plasminogen activator inhibitor 1. <i>Thrombosis and Haemostasis</i> , 2016, 116, 1032-1040.	3.4	14
157	Amplified endogenous plasmin activity resolves acute thrombotic thrombocytopenic purpura in mice. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 2432-2442.	3.8	14
158	Targeting plasminogen activator inhibitor-1 in tetracycline-induced pleural injury in rabbits. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2018, 314, L54-L68.	2.9	14
159	Cloning of a single-chain variable fragment (scFv) switching active plasminogen activator inhibitor-1 to substrate. <i>Gene</i> , 1997, 189, 83-88.	2.2	13
160	Redirection of the reaction between activated protein C and a serpin to the substrate pathway. <i>Thrombosis Research</i> , 2008, 122, 397-404.	1.7	13
161	The Occurrence of Thrombosis in Inflammatory Bowel Disease Is Reflected in the Clot Lysis Profile. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 2540-2548.	1.9	13
162	Inhibition of plasminogen activator inhibitor-1: antibody fragments and their unique sequences as a tool for the development of profibrinolytic drugs. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 298-305.	3.8	12

#	ARTICLE	IF	CITATIONS
163	Activation of the Zymogen to Urokinase-Type Plasminogen Activator Is Associated with Increased Interdomain Flexibility. <i>Journal of Molecular Biology</i> , 2011, 411, 417-429.	4.2	12
164	Biosimilars – terms of use. <i>Current Medical Research and Opinion</i> , 2015, 31, 2325-2330.	1.9	12
165	Molecular mechanism of two nanobodies that inhibit PAI-1 activity reveals a modulation at distinct stages of the PAI-1/plasminogen activator interaction. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 681-692.	3.8	12
166	Bioavailability of different artemisinin tablet formulations in rabbit plasma – correlation with results obtained by an in vitro dissolution method. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 1997, 16, 185-189.	2.8	11
167	Characterization of plasminogen activator inhibitor 1 mutants containing the P13 to P10 region of ovalbumin or antithrombin III: evidence that the P13 residue contributes significantly to the active to substrate transition. <i>BBA - Proteins and Proteomics</i> , 1998, 1387, 291-297.	2.1	11
168	Glycosylation dependent conformational transitions in plasminogen activator inhibitor-1: evidence for the presence of two active conformations. <i>Fibrinolysis and Proteolysis</i> , 2000, 14, 58-64.	1.1	11
169	Enhanced expression of plasminogen activator inhibitor-1 by dedifferentiated thyrocytes. <i>Biochemical and Biophysical Research Communications</i> , 2002, 295, 737-743.	2.1	11
170	The Conversion of Active to Latent Plasminogen Activator Inhibitor-1 Is an Energetically Silent Event. <i>Biophysical Journal</i> , 2005, 88, 2848-2854.	0.5	11
171	Improved Potency and Safety of DNA-Encoded Antibody Therapeutics Through Plasmid Backbone and Expression Cassette Engineering. <i>Human Gene Therapy</i> , 2021, 32, 1200-1209.	2.7	11
172	Influence of oral intake of retinoids on the human plasma fibrinolytic system. <i>Fibrinolysis</i> , 1993, 7, 347-351.	0.5	10
173	Advances in understanding pectin methylesterase inhibitor in kiwi fruit: an immunological approach. <i>Planta</i> , 2011, 233, 287-298.	3.2	10
174	Use of Mouse Models to Study Plasminogen Activator Inhibitor-1. <i>Methods in Enzymology</i> , 2011, 499, 77-104.	1.0	10
175	Systemic inhibition and liver-specific overexpression of PAI-1 failed to improve survival in all-inclusive populations or homogenous cohorts of CLP mice. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 958-969.	3.8	10
176	In vitro and in vivo characterisation of the profibrinolytic effect of an inhibitory anti-rat TAFI nanobody. <i>Thrombosis and Haemostasis</i> , 2014, 111, 824-832.	3.4	10
177	Miniaturized single-cell technologies for monoclonal antibody discovery. <i>Lab on A Chip</i> , 2021, 21, 3627-3654.	6.0	10
178	Structural Insight into the Two-Step Mechanism of PAI-1 Inhibition by Small Molecule TM5484. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1482.	4.1	10
179	Defective TAFI Activation in Hemophilia Exacerbates Vascular Remodeling in Hemophilic Arthropathy. <i>Blood</i> , 2016, 128, 82-82.	1.4	10
180	Hydrogenosomal ATP: AMP phosphotransferase of <i>Trichomonas vaginalis</i> . <i>Comparative Biochemistry and Physiology Part B: Comparative Biochemistry</i> , 1987, 88, 575-580.	0.2	9

#	ARTICLE	IF	CITATIONS
181	Immunological Quantitation of Rabbit Plasminogen Activator Inhibitor-1 in Biological Samples. <i>Thrombosis and Haemostasis</i> , 1999, 82, 1510-1515.	3.4	9
182	Clearance of plasmin-PAI-1 complexes by vascular smooth muscle cells in human aneurysm of the ascending aorta. <i>Cardiovascular Pathology</i> , 2018, 32, 15-25.	1.6	9
183	Population pharmacokinetic-pharmacodynamic model-based exploration of alternative ustekinumab dosage regimens for patients with Crohn's disease. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 323-335.	2.4	9
184	Intratumoral DNA-based delivery of checkpoint-inhibiting antibodies and interleukin 12 triggers T cell infiltration and anti-tumor response. <i>Cancer Gene Therapy</i> , 2022, 29, 984-992.	4.6	9
185	Induction of t-PA Synthesis with intravenous bolus injection of vitamin A palmitate in vitamin a deficient rats. <i>Fibrinolysis</i> , 1992, 6, 243-249.	0.5	8
186	Identification of functional synergism between monoclonal antibodies. Application to the enhancement of plasminogen activator inhibitor-1 neutralizing effects. <i>FEBS Letters</i> , 1997, 416, 373-376.	2.8	8
187	Protonation State of a Single Histidine Residue Contributes Significantly to the Kinetics of the Reaction of Plasminogen Activator Inhibitor-1 with Tissue-type Plasminogen Activator. <i>Journal of Biological Chemistry</i> , 2004, 279, 23007-23013.	3.4	8
188	Species-dependent molecular drug targets in plasminogen activator inhibitor-1 (PAI-1). <i>Thrombosis and Haemostasis</i> , 2009, 102, 609-610.	3.4	8
189	Increased zymogen activity of thrombin-activatable fibrinolysis inhibitor prolongs clot lysis. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1091-1099.	3.8	8
190	Biopharmaceuticals: Reference Products and Biosimilars to Treat Inflammatory Diseases. <i>Therapeutic Drug Monitoring</i> , 2017, 39, 308-315.	2.0	8
191	A Genome-wide Study of Common and Rare Genetic Variants Associated with Circulating Thrombin Activatable Fibrinolysis Inhibitor. <i>Thrombosis and Haemostasis</i> , 2018, 118, 298-308.	3.4	8
192	Structural Insights into the Mechanism of a Nanobody That Stabilizes PAI-1 and Modulates Its Activity. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5859.	4.1	8
193	Potent neutralizing anti-SARS-CoV-2 human antibodies cure infection with SARS-CoV-2 variants in hamster model. <i>iScience</i> , 2022, 25, 104705.	4.1	8
194	Expression, purification, and characterization of recombinant rat plasminogen activator inhibitor-1. <i>Fibrinolysis and Proteolysis</i> , 1997, 11, 37-43.	1.1	7
195	Suppression of plasminogen activator inhibitor 1 (PAI-1) activity levels in rats by monoclonal antibodies. <i>Fibrinolysis and Proteolysis</i> , 1998, 12, 335-339.	1.1	7
196	Immunoassays for the Quantitation of Porcine PAI-1 Antigen and Activity in Biological Fluid Samples. <i>Thrombosis and Haemostasis</i> , 2000, 84, 1082-1086.	3.4	7
197	Cloning and paratope analysis of an antibody fragment, a rational approach for the design of a PAI-1 inhibitor. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 289-297.	3.8	7
198	Study of Recombinant Antibody Fragments and PAI-1 Complexes Combining Protein-Protein Docking and Results from Site-Directed Mutagenesis. <i>Structure</i> , 2007, 15, 1105-1116.	3.3	7

#	ARTICLE	IF	CITATIONS
199	Comparative study of inhibitory antibody derivatives towards thrombin activatable fibrinolysis inhibitor. <i>Thrombosis and Haemostasis</i> , 2009, 102, 69-75.	3.4	7
200	Letter: dry blood spots for anti- $\text{TNF}$ treatment monitoring in IBD. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 1024-1025.	3.7	7
201	Evaluation of the profibrinolytic properties of a bispecific antibody-based inhibitor against human and mouse thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 2069-2071.	3.8	7
202	The rise of oncology biosimilars: from process to promise. <i>Future Oncology</i> , 2019, 15, 3255-3265.	2.4	7
203	DNA-based delivery of anti-DR5 Nanobodies improves exposure and anti-tumor efficacy over protein-based administration. <i>Cancer Gene Therapy</i> , 2021, 28, 828-838.	4.6	7
204	Electroporation outperforms in vivo-jetPEI for intratumoral DNA-based reporter gene transfer. <i>Scientific Reports</i> , 2020, 10, 19532.	3.3	7
205	Tissue Exposure does not Explain Non-Response in Ulcerative Colitis Patients with Adequate Serum Vedolizumab Concentrations. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 988-993.	1.3	7
206	Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians. <i>Journal of Pharmaceutical Policy and Practice</i> , 2021, 14, 53.	2.4	7
207	Elucidation of the epitope of a latency-inducing antibody: identification of a new molecular target for PAI-1 inhibition. <i>Thrombosis and Haemostasis</i> , 2003, 90, 52-8.	3.4	7
208	Effect of Reteplase, $\alpha$ and PAI-1 antibodies on postoperative adhesion formation in a laparoscopic mouse model. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2009, 23, 1018-1025.	2.4	6
209	Immunological methods to study the fibrinolytic system. <i>Fibrinolysis</i> , 1993, 7, 9-10.	0.5	5
210	Structural determinants in the stability of the serpin/proteinase complex. <i>Biochemical and Biophysical Research Communications</i> , 2003, 307, 529-534.	2.1	5
211	Elucidation of the paratope of scFv-8H9D4, a PAI-1 neutralizing antibody derivative. <i>Thrombosis and Haemostasis</i> , 2003, 89, 74-82.	3.4	5
212	Generation of a stable thrombin-activatable fibrinolysis inhibitor deletion mutant exerting full carboxypeptidase activity without activation. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 1084-1089.	3.8	5
213	Quantitation of Vervet Monkey ( <i>Chlorocebus aethiops</i> ) plasminogen activator inhibitor-1 in plasma and platelets. <i>Thrombosis and Haemostasis</i> , 2006, 95, 902-903.	3.4	5
214	Importance of manufacturing consistency of the glycosylated monoclonal antibody adalimumab (Humira $\text{\textcircled{R}}$ ) and potential impact on the clinical use of biosimilars. <i>GaBI Journal</i> , 2016, 5, 70-73.	0.3	5
215	Model-Informed Precision Dosing during Infliximab Induction Therapy Reduces Variability in Exposure and Endoscopic Improvement between Patients with Ulcerative Colitis. <i>Pharmaceutics</i> , 2021, 13, 1623.	4.5	4
216	Plasminogen activator inhibitor 1 (PAI-1) in its active conformation: crystallization and preliminary X-ray diffraction data. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 1999, 55, 574-576.	2.5	3

#	ARTICLE	IF	CITATIONS
217	Site-directed Targeting of Plasminogen Activator Inhibitor-1 as an Example for a Novel Approach in Rational Drug Design. <i>Journal of Biological Chemistry</i> , 2004, 279, 20447-20450.	3.4	3
218	Conformational (in)stability of rat vs. human activated thrombin activatable fibrinolysis inhibitor. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1426-1428.	3.8	3
219	Development of an immunological toolbox to detect endogenous and exogenous pectin methylesterase in plant-based food products. <i>Food Research International</i> , 2011, 44, 931-939.	6.2	3
220	Glycosylation influences the stability of human plasminogen activator inhibitor-1. <i>Blood Coagulation and Fibrinolysis</i> , 2012, 23, 570-572.	1.0	3
221	Both plasma basic carboxypeptidases, carboxypeptidase B2 and carboxypeptidase N, regulate vascular leakage activity in mice. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 238-244.	3.8	3
222	Higher Drug Exposure During the First 24 Weeks of Ustekinumab Treatment Is Associated With Endoscopic Remission in Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 838-840.e2.	4.4	3
223	Conformational studies on forms of plasminogen activator inhibitor, PAI-1. <i>Fibrinolysis</i> , 1994, 8, 17.	0.5	2
224	Construction and characterization of plasminogen activator inhibitor-1 mutants in which part of the active site loop is deleted. <i>Fibrinolysis and Proteolysis</i> , 1997, 11, 265-271.	1.1	2
225	Induction of conformational changes within crystals of plasminogen activator inhibitor-1 (PAI-1). <i>Fibrinolysis and Proteolysis</i> , 1999, 13, 203-207.	1.1	2
226	Immunological toolbox available for in situ exploration of pectic homogalacturonan and its modifying enzymes in fruits and vegetables and their derived food products. <i>Innovative Food Science and Emerging Technologies</i> , 2012, 15, 72-80.	5.6	2
227	Development of a liquid chromatography/mass spectrometry assay for the bacterial transglycosylation reaction through measurement of Lipid II. <i>Electrophoresis</i> , 2015, 36, 2841-2849.	2.4	2
228	Lys 42/43/44 and Arg 12 of thrombin-activable fibrinolysis inhibitor comprise a thrombomodulin exosite essential for its antifibrinolytic potential. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1509-1517.	3.4	2
229	S62798, a potent TAFIa inhibitor, accelerates endogenous fibrinolysis in a murine model of pulmonary thromboembolism. <i>Thrombosis Research</i> , 2021, 204, 81-87.	1.7	2
230	Prevention of Premature Fibrinolysis and Reduction of Bleeding in Vivo in Hemophilia with Inhibitors By a Stabilized TAFI Variant. <i>Blood</i> , 2014, 124, 694-694.	1.4	2
231	Quantitation of Vervet monkey ( <i>Chlorocebus aethiops</i> ) plasminogen activator inhibitor-1 in plasma and platelets. <i>Thrombosis and Haemostasis</i> , 2006, 95, 902-3.	3.4	2
232	Therapeutic drug monitoring in dermatology: the way towards dose optimization of secukinumab in chronic plaque psoriasis. <i>Clinical and Experimental Dermatology</i> , 2022, 47, 1324-1336.	1.3	2
233	Comparative analysis of the proteinase specificity in wild-type and stabilized plasminogen activator inhibitor-1: evidence for contribution of intramolecular flexibility. <i>Biochemical and Biophysical Research Communications</i> , 2004, 321, 746-751.	2.1	1
234	Study of Recombinant Antibody Fragments and PAI-1 Complexes Combining Protein-Protein Docking and Results from Site-Directed Mutagenesis. <i>Structure</i> , 2007, 15, 1339.	3.3	1

#	ARTICLE	IF	CITATIONS
235	Monoclonal antibodies: indications, budget impact and use. <i>Journal of Pharmaceutical Health Services Research</i> , 2010, 1, 123-130.	0.6	1
236	Long-term in vivo expression of trastuzumab following intramuscular electrotransfer of the encoding DNA in mice. , 2015, 3, .		1
237	Generation and characterization of monoclonal antibodies against the N-terminus of alpha-2-antiplasmin. <i>PLoS ONE</i> , 2018, 13, e0196911.	2.5	1
238	Plasminogen Activators Inhibitors. , 2003, , 47-66.		1
239	A model of the active form of plasminogen-activator-inhibitor-1. <i>Fibrinolysis</i> , 1994, 8, 103.	0.5	0
240	Various approaches to standardization and the importance of measurement accuracy. <i>Fibrinolysis</i> , 1996, 10, 113-116.	0.5	0
241	High Levels of Thrombin Activatable Fibrinolysis Inhibitor and Plasminogen Activator Inhibitor Are a Risk Factor for Thromboembolism: A Case-Control Study in IBD Patients. <i>Gastroenterology</i> , 2011, 140, S-435-S-436.	1.3	0
242	P033 Prevention of recurrent <i>Clostridium difficile</i> infection by neutralizing monoclonal antibodies in a hamster relapse model. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S77-S78.	1.3	0
243	Clot stability and fibrin deposition is strongly reduced in mice in which mouse TAFI is replaced by human TAFI. <i>Thrombosis Research</i> , 2014, 133, 1166-1168.	1.7	0
244	Prevention of Serpin Misfolding by RNA Aptamers. <i>Cell Chemical Biology</i> , 2016, 23, 639-640.	5.2	0
245	Market Uptake Models Of Biosimilars And Off-Patent Biological Medicines. <i>Value in Health</i> , 2016, 19, A452.	0.3	0
246	Selective neutralization of the serpin protease nexinâ€1 by a specific monoclonal antibody. <i>British Journal of Haematology</i> , 2016, 172, 631-633.	2.5	0
247	Su433 MODEL-BASED IDENTIFICATION OF AN OPTIMIZED USTEKINUMAB DOSAGE REGIMEN FOR PATIENTS WITH CROHN'S DISEASE. <i>Gastroenterology</i> , 2021, 160, S-687.	1.3	0
248	Common or distinct INN for biosimilars? Only characteristics of the active substance prior to formulation should be considered. <i>GaBI Journal</i> , 2014, 3, 8-8.	0.3	0
249	Defective TAFI Activation in Hemophilia Worsens Joint Bleeding. <i>Blood</i> , 2016, 128, 3752-3752.	1.4	0
250	Abstract 348: Lys 42, 43, 44 and Arg 12 of Thrombin Activable Fibrinolysis Inhibitor Comprise Thrombomodulin Binding Exosite Essential for Exerting Its Antifibrinolytic Activity. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, .	2.4	0
251	Editorial: Gastrointestinal 2020: Novel inflammatory bowel disease treatments and therapeutic drug monitoring. <i>Current Opinion in Pharmacology</i> , 2020, 55, iii-vi.	3.5	0
252	586â€...Intratatumoral DNA-based gene transfer as an efficient delivery approach to combine checkpoint-inhibiting antibodies with interleukin 12. , 2020, , .		0

#	ARTICLE	IF	CITATIONS
253	Novel ELISA for the specific detection of protease NEXIN <sup>®</sup> 1 in human biological samples. Research and Practice in Thrombosis and Haemostasis, 2022, 6, .	2.3	0